0%
Print report
Variant interpretation report

SLC6A19 c.517G>A, p.Asp173Asn

NM_001003841.3:c.517G>A NP_001003841.1:p.(Asp173Asn) Missense · exon 4 View identifiers
Classification
Uncertain significance

Variant description:

The SLC6A19 NM_001003841.3:c.517G>A (NP_001003841.1:p.(Asp173Asn)) missense variant has not previously been reported in somatic cancers (COSMIC). Experimental evidence: D173N showed relatively low amino-acid transport in oocytes compared with wild type, with orthogonal assays demonstrating altered transport and surface expression. Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About SLC6A19

SLC6A19 encodes B0AT1, a membrane protein that transports most neutral amino acids into epithelial cells, especially in the intestine and kidney. Changes in this gene can cause Hartnup disorder, an inherited condition that may lead to pellagra-like symptoms, balance problems, and psychiatric symptoms; SLC6A19 has no established role in cancer.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 1 Benign evidence criteria: 1
Pathogenic criteria applied · 1
PS3Supporting
PS3 · supporting

Met at supporting: D173N showed relatively low amino-acid transport in oocytes compared with wild type, with orthogonal assays demonstrating altered transport and surface expression.

Benign criteria applied · 1
BP4Moderate
BP4 · moderate

Met at moderate strength: REVEL 0.179 meets the generic BP4 moderate threshold of <=0.183 for missense variants.

Recorded classification: Uncertain significance

VUS: PS3 supporting plus BP4 moderate do not satisfy any generic ACMG/AMP pathogenic, likely pathogenic, benign, or likely benign combination rule.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
5,008 / 1,613,638 alleles

gnomAD v4.1: 5,008 / 1,613,638 alleles. Recorded AF 0.00310355. Recorded homozygote count 12.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.00156212; MAF= 0.15621%, 441/282308 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 0.00301555; MAF= 0.30156%, 389/128998 alleles, homozygotes = 0); grpmax FAF= 0.00280627.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.0018464212012599109, 34/18414 alleles, homozygotes = 0).

No screenshot for this evidence
REVEL score
0.179 recorded score

Recorded REVEL score: 0.179. Refer to the recorded PP3/BP4 rationale for interpretation.

ClinVar submissions
20 reported laboratory submissions

18 Pathogenic · 1 Likely pathogenic · 1 Uncertain significance. ClinVar API review status: criteria provided, multiple submitters, no conflicts.

Context only ClinVar ↗
No screenshot for this evidence
Functional evidence
Not recorded

No standalone functional evidence summary is recorded in evidence_summary.functional.

COSMIC
Cancer Hotspots
Somatic evidence
No matching record reported

This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.

28 criteria with recorded statuses: 2 met · 8 not met · 14 not assessed · 4 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

No reliable proband-level de novo, parental-testing, variant-specific segregation, or affected-relative non-segregation evidence was available for these four criteria.

The available D173N literature describes recurrence in unrelated families and general recessive cosegregation, but does not supply the family-level genotype and phenotype data required for a criterion assignment.

No VCEP covers SLC6A19; generic ACMG/AMP rules govern.

The available literature and population data do not provide a verifiable PS4 case-control estimate or the individual phenotype needed for PP4.

PP5 and BP6 are not met because the exact variant has zero ClinVar expert-panel submissions.

Population evidence supports none of the four requested criteria: BA1 and BS1 thresholds are not reached, PM2 is contradicted by multiple gnomAD datasets, and BS2 cannot be established from aggregate homozygote counts without individual healthy-adult evidence.

Met · 2

PS3 SupportingACMG_2015Met at supporting: D173N showed relatively low amino-acid transport in oocytes compared with wild type, with orthogonal assays demonstrating altered transport and surface expression. Details ▾Hide ▴
Reasoning

PS3 is met at supporting strength. PMID:19185582 directly studied SLC6A19 p.Asp173Asn (D173N) in Xenopus laevis oocytes using wild-type and mutant constructs, with radiolabeled L-isoleucine uptake, two-microelectrode voltage clamp, surface-protein biotinylation, and coimmunoprecipitation. D173N had relatively low transport activity when expressed alone; coexpression with ACE2 increased transport and surface expression, whereas collectrin did not, supporting a variant-specific defect in transporter function and trafficking in a biologically relevant assay system. The study included wild-type comparator constructs, accessory-protein controls, pooled independent experiments, and orthogonal functional readouts. Supporting rather than strong strength is used because the available evidence is a research assay report rather than a validated, reproducible clinical diagnostic-laboratory assay, and no quantitative effect size or independent replication threshold is supplied in the governing rules.

Rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.
Evidence considered
  • Camargo et al. 2009, Table 1; Results section 'Differential Interaction of Accessory Proteins With B0AT1 Hartnup Mutations'; Figures 2B, 2D, and 3: the exact D173N variant showed relatively low transport activity when expressed alone, ACE2 increased transport and surface expression, and collectrin did not.
  • The assay used Xenopus laevis oocytes expressing human wild-type or mutant B0AT1 alone or with collectrin or ACE2, with radiolabeled L-isoleucine uptake, two-microelectrode voltage clamp, surface-protein biotinylation, and coimmunoprecipitation; influx assays included 13–31 oocytes and TEVC assays included 9–11 oocytes.
Still missing
  • No validated clinical diagnostic-laboratory assay or independent replication meeting a stronger calibration threshold is documented.
  • The extracted evidence does not provide quantitative transport effect sizes or complete control values.
Sources
BP4 ModerateACMGMet at moderate strength: REVEL 0.179 meets the generic BP4 moderate threshold of <=0.183 for missense variants. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NM_001003841.3:c.517G>A (NP_001003841.1:p.(Asp173Asn)), so the generic missense path requires REVEL and does not use SpliceAI. REVEL is 0.179, which meets the supplied generic BP4 moderate threshold of <= 0.183; therefore BP4 is met at moderate strength. The SpliceAI result is not counted on this path, and BayesDel is not used because no generic ACMG-strength calibration is established.

Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc) ... BP4 (moderate): <= 0.183 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Consequence classification: missense variant NM_001003841.3:c.517G>A, producing NP_001003841.1:p.(Asp173Asn).
  • Local REVEL lookup reports score 0.179 for chr5:1212338 G>A.
  • The supplied generic calibration gives BP4 moderate at REVEL <= 0.183; ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet; PMID:36413997).
  • SpliceAI max delta 0.005 was not used because the governing generic path for a missense variant is REVEL only; BayesDel was not used because no generic ACMG-strength calibration is established.
Sources
revel

Not met · 8 · evaluated, threshold not reached

PM2 ACMGNot met: gnomAD v4.1 AF is 0.00310355, above the <=0.0001 PM2 threshold, with 12 homozygotes observed. Details ▾Hide ▴
Reasoning

PM2 is not met. The variant is present in population controls at frequencies well above the generic recessive PM2 supporting threshold of <=0.0001: gnomAD v4.1 all-comers AF=0.00310355 (5008/1613638 alleles; 12 homozygotes), gnomAD v2.1 non-cancer exome AF=0.00152619 (361/236536 alleles; no homozygotes), and gnomAD v3.1 non-cancer AF=0.0016636 (246/147872 alleles; no homozygotes).

Rule
PM2: Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium. ... PM2 (supporting): <= 0.0001 — SVI recommendation to downgrade PM2 to Supporting (ClinGen SVI 2020) (PMID:25741868)
Evidence considered
  • gnomAD v4.1 all-comers: AF=0.00310355, 5008/1613638 alleles, homozygotes=12.
  • gnomAD v2.1 non-cancer exomes: AF=0.00152619, 361/236536 alleles, homozygotes=0.
  • gnomAD v3.1 non-cancer genomes: AF=0.0016636, 246/147872 alleles, homozygotes=0; v3 has no exome cohort.
  • The generic PM2 calibration supplied for this case is <=0.0001; presence above this extremely-low-frequency threshold does not support PM2.
Sources
PP3 ACMGNot met: REVEL 0.179 is below the generic PP3 supporting threshold of >=0.644 for missense variants. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NM_001003841.3:c.517G>A (NP_001003841.1:p.(Asp173Asn)), so the generic missense path requires REVEL and does not use SpliceAI. REVEL is 0.179, below the generic PP3 supporting threshold of >= 0.644; therefore PP3 is not met. BayesDel is not used because no generic ACMG-strength calibration is established, and the SpliceAI result is not counted on the missense path.

Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.). ... PP3 (supporting): >= 0.644 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Consequence classification: missense variant NM_001003841.3:c.517G>A, producing NP_001003841.1:p.(Asp173Asn).
  • Local REVEL lookup reports score 0.179 for chr5:1212338 G>A.
  • The supplied generic calibration gives PP3 supporting at REVEL >= 0.644; ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet; PMID:36413997).
  • SpliceAI max delta 0.005 was not used because the governing generic path for a missense variant is REVEL only; BayesDel was not used because no generic ACMG-strength calibration is established.
Sources
revel
PP5 ACMG_2015Not met: ClinVar has 0 expert-panel submissions for the exact variant, so laboratory and aggregate pathogenic labels cannot trigger PP5. Details ▾Hide ▴
Reasoning

The governing rule is: "Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation." The exact variant has ClinVar Pathogenic and Likely pathogenic laboratory submissions, but the audit records zero expert-panel submissions. Ordinary laboratory submissions, aggregate ClinVar labels, and non-expert assertions do not satisfy the required reputable-source basis for PP5 under the specified generic rule.

Rule
Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar exact-variant audit: Pathogenic is reported by 18 clinical laboratories and Likely pathogenic by 1 clinical laboratory, but expert_panel_submissions = 0.
  • The available ClinVar assertions are ordinary laboratory submissions or aggregate labels, not an exact-variant expert-panel classification.
Sources
BA1 ACMGNot met: gnomAD v4.1 grpmax FAF is 0.00395819, below the 0.05 BA1 threshold, with 1,179,944 observed European non-Finnish alleles. Details ▾Hide ▴
Reasoning

BA1 is not met. The governing default requires allele frequency >=0.05, and the appropriate filtering metric is the gnomAD v4.1 grpmax FAF of 0.00395819 (0.395819%), based on the European non-Finnish population with 1,179,944 observed alleles; this is below 0.05 and the qualifying population exceeds the 2,000-observed-allele minimum. The gnomAD v2.1 non-cancer exome grpmax FAF is also only 0.00283522. The variant has a documented pathogenic association with autosomal-recessive Hartnup disorder, so the lower frequency and disease association provide no basis for a stand-alone benign BA1 call.

Rule
BA1 (stand-alone): >= 0.05 — ACMG/AMP 2015 stand-alone benign allele frequency (PMID:25741868)
Evidence considered
  • gnomAD v4.1 all-comers: AF=0.00310355, 5008/1613638 alleles, homozygotes=12; grpmax FAF=0.00395819 in European non-Finnish individuals (4784/1179944 alleles).
  • gnomAD v2.1 non-cancer exomes: AF=0.00152619, 361/236536 alleles, homozygotes=0; grpmax FAF=0.00283522.
  • The generic BA1 calibration supplied for this case is >=0.05; the filtering allele frequency, not the popmax point estimate, is used.
Sources
BS1 ACMGNot met: gnomAD v4.1 grpmax FAF is 0.00395819, below the generic 0.01 BS1 default, and the allele is a documented common recessive Hartnup disease allele. Details ▾Hide ▴
Reasoning

BS1 is not met. The gnomAD v4.1 filtering grpmax FAF is 0.00395819, below the generic 0.01 default, and the gnomAD v2.1 non-cancer exome grpmax FAF is 0.00283522. The frequency is therefore not greater than the generic disorder-expectation threshold supplied here. This is an autosomal-recessive disorder, and the D173N allele is documented as a common Hartnup disease allele in populations of European origin; consequently, the observed carrier frequency is not by itself evidence that the allele is too common for the disorder. No gene-specific maximum-credible-frequency calculation is available to justify BS1 above the default.

Rule
BS1: Allele frequency is greater than expected for the disorder. ... BS1 (strong): >= 0.01 — Generic SVI default; per-gene derivation preferred (Whiffin et al. 2017) (PMID:28518168)
Evidence considered
  • gnomAD v4.1 all-comers: grpmax FAF=0.00395819 in European non-Finnish individuals, below the generic BS1 default of 0.01.
  • gnomAD v2.1 non-cancer exomes: grpmax FAF=0.00283522, also below 0.01.
  • Azmanov et al. 2007, PMID:17555458, abstract: the D173N allele is present in 42% of Hartnup chromosomes from apparently unrelated families from Australia and North America, supporting a common pathogenic recessive allele rather than an automatic benign frequency interpretation.
  • The generic BS1 calibration supplied for this case is >=0.01; the filtering grpmax FAF is used rather than a popmax point estimate.
Sources
BS3 ACMG_2015Not met: D173N showed relatively low transporter activity and altered surface expression rather than demonstrating no damaging effect on protein function or splicing. Details ▾Hide ▴
Reasoning

BS3 is not met. The variant-specific functional study did not show no damaging effect on protein function or splicing; instead, D173N had relatively low B0AT1 transport activity when expressed alone and altered surface expression and transport responses to ACE2 compared with controls. No benign functional result for D173N is documented.

Rule
Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • Camargo et al. 2009, Table 1; Results section 'Differential Interaction of Accessory Proteins With B0AT1 Hartnup Mutations'; Figures 2B, 2D, and 3: the D173N result was reduced/altered function, not a normal-function result, and no splicing assay was reported.
Sources
BP1 ACMG_2015Not met: recurrent disease-associated missense D173N and direct functional testing show that SLC6A19 disease is not established as primarily truncating. Details ▾Hide ▴
Reasoning

BP1 is not supported because the available SLC6A19 disease literature documents a recurrent missense disease allele, D173N, including its occurrence in Hartnup disorder families, and functional studies directly evaluate the D173N missense protein. This evidence is inconsistent with treating SLC6A19 as a gene for which disease is known primarily through truncating variants.

Rule
Missense variant in a gene for which primarily truncating variants are known to cause disease.
Evidence considered
  • Azmanov et al. reports the D173N missense allele in 42% of Hartnup chromosomes from apparently unrelated families.
  • Camargo et al. directly evaluates the SLC6A19 D173N missense protein in Xenopus laevis oocyte transport and surface-expression assays.
Sources
BP6 ACMG_2015Not met: no exact-variant expert-panel benign or likely benign classification is present; available ClinVar submissions are non-expert assertions. Details ▾Hide ▴
Reasoning

The governing rule is: "Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation." The exact variant has no expert-panel ClinVar submission and no qualifying exact-variant expert-panel benign or likely benign classification. The available laboratory submissions are predominantly pathogenic or likely pathogenic, with one uncertain-significance submission, so BP6 is not met.

Rule
Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar exact-variant audit reports expert_panel_submissions = 0; the submission summary contains Pathogenic, Likely pathogenic, and Uncertain significance, with no benign or likely benign expert-panel assertion.
  • Ordinary laboratory submissions, aggregate labels, and non-expert assertions are excluded from BP6 under the specified generic rule.
Sources

Not assessed · 14 · no assessment recorded

PS1 ACMG_2015Not assessed: D173N is reported, but no pathogenic alternate-nucleotide change producing the same Asp173Asn substitution is documented. Details ▾Hide ▴
Reasoning

The variant is NP_001003841.1:p.(Asp173Asn), and the case contains reports of this exact D173N allele, but no evidence identifies a previously established pathogenic variant producing the same amino-acid change through a different nucleotide change. The available evidence therefore does not establish the codon-level comparison required for PS1; the exact variant's ClinVar classification cannot itself be used as PS1 evidence.

Rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change. ... Example: Val->Leu caused by either G>C or G>T in the same codon. ... Caveat: Beware of changes that impact splicing rather than at the amino acid/protein level.
Evidence considered
  • The normalized variant is NM_001003841.3:c.517G>A, NP_001003841.1:p.(Asp173Asn).
  • ClinVar record 2019 and Azmanov et al. report the exact D173N allele, but neither source documents a distinct nucleotide change producing the same amino-acid substitution; an exact-variant classification is not substituted for PS1 evidence.
Still missing
  • A validated pathogenic alternate nucleotide change encoding p.Asp173Asn is not documented.
Sources
PS2 ACMG_2015Not assessed: no documented affected proband with confirmed maternity and paternity, parental genotypes, and absent family history is available. Details ▾Hide ▴
Reasoning

The available evidence does not document that NM_001003841.3:c.517G>A (p.Asp173Asn) occurred de novo in an affected proband. There is no case-level evidence confirming both maternity and paternity, no documented parental genotypes, and no usable family-history statement establishing absence of a family history. Therefore the required PS2 evidence cannot be assessed.

Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
  • The case evidence identifies the variant as SLC6A19 c.517G>A (p.Asp173Asn) and describes Hartnup disorder as autosomal recessive, but provides no individual-level de novo observation or parental testing result.
  • ClinVar submissions and cited literature do not provide a documented maternity- and paternity-confirmed de novo occurrence for this variant.
Still missing
  • Affected-proband case report or clinical record with phenotype consistent with the disease
  • Parental testing confirming both maternity and paternity
  • Documented absence of relevant family history
PS4 ACMG_2015Not assessed: D173N is reported in Hartnup families, but no verifiable matched control count, OR/RR, or 95% CI is available for the >5.0 PS4 requirement. Details ▾Hide ▴
Reasoning

The governing rule is: "The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls." ACMG/AMP further requires: "Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0." PMID:17555458 reports that D173N is present in 42% of Hartnup chromosomes from apparently unrelated families, but the available evidence does not provide a matched control count, case count sufficient for a 2x2 table, OR/RR, or 95% CI. The literature packet's PS4 index points to PMID:29431110 and PMID:30487145, but neither source has a source-registry entry or fetched full text in this case, so their case-control status cannot be verified. gnomAD provides population frequencies (0.00156212 overall in v2.1; 0.00310355 overall and 0.00405443 in NFE in v4.1) but cannot by itself establish the required affected-versus-control comparison. Therefore PS4 cannot be adjudicated from the available evidence.

Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
  • Azmanov et al. 2007 (PMID:17555458) abstract: "One mutation, the D173N allele, is present in 42% of Hartnup chromosomes from apparently unrelated families from both Australia and North America." This is affected-family prevalence, not a complete case-control comparison.
  • gnomAD v2.1 reports NM_001003841.3:c.517G>A at AF 0.00156212 overall (441/282308 alleles) and AF 0.00301555 in European non-Finnish individuals (389/128998 alleles).
  • gnomAD v4.1 reports AF 0.00310355 overall (5008/1613638 alleles) and AF 0.00405443 in European non-Finnish individuals (4784/1179944 alleles; 12 homozygotes).
  • No OR/RR and no 95% confidence interval can be calculated from the available case and control information.
Still missing
  • Obtain the full text or reliable numerical data from PMID:29431110 and PMID:30487145.
  • Obtain affected and matched-control counts, or a reported OR/RR with its 95% CI, for the exact D173N variant.
Sources
PM1 ACMG_2015Not assessed: no approved domain or hotspot evidence places residue 173 in a critical region without benign variation. Details ▾Hide ▴
Reasoning

No VCEP covers SLC6A19 and vcep_materials.json has no domain table. The case's cancer-hotspot search reports no statistically significant hotspot for SLC6A19 D173, while the supplied evidence does not establish that residue 173 lies in a critical, well-established functional domain without benign variation. PM1 cannot be assigned from general transporter topology or conservation alone.

Rule
Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation.
Evidence considered
  • The case reports no statistically significant Cancer Hotspots result for SLC6A19 D173.
  • No VCEP domain table is present for SLC6A19, and the available literature does not provide a sufficiently defined critical functional domain at residue 173 together with the required absence of benign variation.
Still missing
  • No authoritative critical-domain annotation covering SLC6A19 residue 173 was supplied.
  • No evidence establishes absence of benign variation in a critical domain containing residue 173.
Sources
PM3 ACMG_2015Not assessed: no affected-proband observation with a pathogenic variant confirmed in trans by parental or offspring phase testing is documented. Details ▾Hide ▴
Reasoning

SLC6A19-related Hartnup disorder is described as autosomal recessive, and the c.517G>A (p.Asp173Asn/D173N) allele is reported in the literature. However, the available evidence does not document an affected proband carrying this variant in trans with a pathogenic variant, nor does it provide parent or offspring testing establishing phase. The criterion therefore cannot be assessed from the available case-specific evidence.

Rule
For recessive disorders, detected in trans with a pathogenic variant ... Note: This requires testing of parents (or offspring) to determine phase.
Evidence considered
  • Azmanov et al. 2007 (PMID:17555458) describes Hartnup disorder as inherited in a simple recessive manner and identifies D173N as a common Hartnup allele, but the available record does not establish a qualifying affected-proband trans pairing or phase for this case.
  • Azmanov et al. 2008 (PMID:18484095) discusses recessive SLC6A19 disease and cosegregation, but the available evidence does not specify a c.517G>A affected-proband genotype with a pathogenic allele in trans or parental phase testing.
Still missing
  • Affected-proband-level genotype data identifying a second pathogenic SLC6A19 variant are not available.
  • Parental or offspring testing establishing that c.517G>A is in trans with a pathogenic variant is not available.
Sources
PM5 ACMG_2015Not assessed: no confirmed pathogenic alternate missense substitution at residue 173 is documented; the known D173N reports are the target change itself. Details ▾Hide ▴
Reasoning

The target is p.Asp173Asn. The case's PM5 candidate collection contains zero same-residue candidates and no confirmed pathogenic alternate missense substitution at residue 173 is identified in the supplied evidence. The exact D173N reports are not a different missense change and therefore cannot establish PM5.

Rule
Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before. ... Example: Arg156His is pathogenic; now you observe Arg156Cys. ... Caveat: Beware of changes that impact splicing rather than at the amino acid/protein level.
Evidence considered
  • The PM5 candidate file reports zero total candidates and zero same-residue candidates for SLC6A19 p.(D173N).
  • Azmanov et al. reports the D173N allele itself, not a different missense substitution at residue 173.
Still missing
  • A validated pathogenic missense variant with a different amino-acid substitution at residue 173 is not documented.
Sources
pm5_candidatesPMID:17555458 ↗
PM6 ACMG_2015Not assessed: no affected-patient de novo observation is documented, even without parental maternity and paternity confirmation. Details ▾Hide ▴
Reasoning

The available evidence does not document an assumed de novo occurrence of NM_001003841.3:c.517G>A (p.Asp173Asn) in an affected patient. No proband-level de novo observation or parental genotype information is provided, so there is no basis to apply PM6.

Rule
Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
  • The case evidence contains no individual-level report stating that this variant was assumed de novo in an affected patient.
  • The available literature and ClinVar record provide no usable parental-origin observation for this variant.
Still missing
  • Affected-patient report documenting the variant as de novo
  • Parental testing or a documented statement that parental origin was not confirmed
PP1 ACMG_2015Not assessed: papers mention D173N in unrelated families and recessive cosegregation, but provide no variant-specific affected-member genotypes or informative-meiosis count. Details ▾Hide ▴
Reasoning

The abstract for PMID:17555458 states that the D173N allele occurs in 42% of Hartnup chromosomes from apparently unrelated families, but this is not a family-level segregation result. The abstract for PMID:18484095 states that SLC6A19 mutations cosegregated with disease in the predicted recessive manner, while also noting that not all causative alleles were identified in all affected individuals; it does not provide variant-specific affected-member genotypes, unaffected-member genotypes, or a count of informative meioses for c.517G>A. Thus the required multiple-affected-family cosegregation evidence is insufficient for PP1.

Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease. ... May be used as stronger evidence with increasing segregation data.
Evidence considered
  • Persistence of the common Hartnup disease D173N allele in populations of European origin, abstract: the D173N allele is present in 42% of Hartnup chromosomes from apparently unrelated families from Australia and North America; this describes recurrence in families, not cosegregation within affected families.
  • Further evidence for allelic heterogeneity in Hartnup disorder, abstract: SLC6A19 mutations have been shown to cosegregate with disease in the predicted recessive manner, but not all causative alleles were identified in all affected individuals; no variant-specific pedigree or meiosis count is supplied in the available evidence.
Still missing
  • Variant-specific pedigrees or family-level genotype data
  • At least multiple affected family members with phenotype and genotype status
  • Informative meioses and segregation details sufficient to judge strength
Sources
PP2 ACMG_2015Not assessed: the evidence lacks both a gene-level low-benign-missense measure and a systematic demonstration that missense is the common disease mechanism. Details ▾Hide ▴
Reasoning

The supplied case evidence does not provide a gene-level benign-missense constraint measure or a systematic assessment showing that missense variants are a common disease mechanism for SLC6A19. Reports of the D173N missense allele and functional studies establish that missense variation exists in disease-related literature, but they do not establish both PP2 conditions.

Rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
Evidence considered
  • Azmanov et al. reports a recurrent SLC6A19 D173N missense allele, and Camargo et al. functionally studies D173N, but these variant-specific observations do not quantify the gene's benign missense rate or establish the complete disease mechanism spectrum.
  • No applicable gene-level missense constraint threshold or systematic missense-mechanism analysis is present in the supplied evidence.
Still missing
  • No gene-level measure or curated analysis establishes a low rate of benign missense variation.
  • No systematic disease-variant spectrum establishes missense variants as a common mechanism.
Sources
PP4 ACMG_2015Not assessed: Hartnup disorder is named, but no individual phenotype or family-history details establish the highly specific PP4 requirement. Details ▾Hide ▴
Reasoning

The governing rule is: "Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology." The case materials identify Hartnup disorder as the relevant disease context, but they do not provide an individual patient's phenotype, family history, or clinical findings that can be assessed for high specificity. A gene-level disease description or the variant's ClinVar condition label is insufficient to apply PP4.

Rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Evidence considered
  • ClinVar identifies the exact variant as associated with Hartnup disorder in some submissions, but the submission condition label is not a patient phenotype.
  • Seow et al. 2004 (PMID:15286788) describes Hartnup disorder as clinically variable; the available extract does not provide this case's individual phenotype or family history.
Still missing
  • Obtain the patient's clinical phenotype and relevant family history.
  • Document why the phenotype is highly specific for Hartnup disorder rather than a nonspecific amino-acid transport presentation.
Sources
BS2 ACMG_2015Not assessed: gnomAD v4.1 reports 12 homozygotes, but their adult health status, ages, phenotypes, and expected early full penetrance are not documented. Details ▾Hide ▴
Reasoning

BS2 is not assessed. gnomAD v4.1 reports 12 homozygotes, including 12 in European non-Finnish individuals, but the available population record does not establish that these homozygotes are healthy adults, their ages, their clinical phenotypes, or that full penetrance is expected at an early age. A population-control homozygote count alone therefore does not satisfy the full BS2 requirement.

Rule
Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.
Evidence considered
  • gnomAD v4.1 reports homozygotes=12 overall and 12 in the European non-Finnish population (4784/1179944 alleles).
  • The gnomAD population summary does not identify the homozygotes as healthy adults or provide individual ages and phenotypes.
Still missing
  • Individual-level age, health, and phenotype data for the 12 gnomAD v4.1 homozygotes are unavailable.
Sources
BS4 ACMG_2015Not assessed: no affected, variant-negative relatives or family-level non-segregation analysis is documented. Details ▾Hide ▴
Reasoning

No affected family members lacking NM_001003841.3:c.517G>A (p.Asp173Asn) are documented. The available evidence contains no pedigree with phenotype-positive, variant-negative relatives and no family-level non-segregation analysis. Therefore lack of segregation cannot be assessed.

Rule
Lack of segregation in affected members of a family.
Evidence considered
  • The available case and literature evidence does not report affected relatives who test negative for the variant.
  • No family-level analysis is available to distinguish true lack of segregation from phenocopy or the autosomal-recessive inheritance context.
Still missing
  • Pedigree containing affected relatives
  • Genotype results for affected relatives
  • Clinical assessment sufficient to exclude phenocopies
BP2 ACMG_2015Not assessed: no documented cis or trans observation with a pathogenic variant and confirmed phase meets the BP2 definition. Details ▾Hide ▴
Reasoning

The available evidence does not document c.517G>A (p.Asp173Asn/D173N) in trans with a pathogenic variant in a fully penetrant dominant SLC6A19 disorder, or in cis with a pathogenic variant under any inheritance pattern. The disease context is recessive, but no qualifying cis or trans allelic observation and phase result is provided; therefore BP2 cannot be assessed.

Rule
Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Still missing
  • No affected or unaffected individual-level genotype record establishes a qualifying cis or trans pathogenic-variant pairing.
  • Phase information for any additional pathogenic variant is not available.
BP5 ACMG_2015Not assessed: no affected case with this variant and a confirmed alternate molecular diagnosis is documented. Details ▾Hide ▴
Reasoning

The governing rule is: "Variant found in a case with an alternate molecular basis for disease." The case materials do not identify an affected case carrying this variant together with a confirmed alternate molecular diagnosis, and no qualifying alternate molecular basis can be inferred from ClinVar labels, population frequency, or functional literature.

Rule
Variant found in a case with an alternate molecular basis for disease.
Evidence considered
  • No case-level alternate molecular diagnosis is documented in the available evidence.
  • Population observations and functional studies do not establish the BP5 clinical scenario.
Still missing
  • Obtain case-level molecular diagnostic data showing an alternate cause of the patient's disease while the exact variant is present.
Not applicable · 4· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant. Details ▾Hide ▴
Reasoning

PVS1 (ClinGen SVI PVS1 recommendations, PMC6185798, pvs1_generic_framework) applies only to null variant classes — nonsense, frameshift, canonical ±1/2 splice-consensus, translation-initiation-codon loss, and stop-loss variants — each expected to trigger nonsense-mediated decay or otherwise abolish normal protein function. NM_001003841.3:c.517G>A in SLC6A19 is a missense substitution predicted to produce NP_001003841.1:p.(Asp173Asn). As a result, no null-variant mechanism (nonsense-mediated decay, truncation, or canonical splice disruption) is triggered by this variant class, so PVS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PVS1 for SLC6A19, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_null_variant_class
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PM4 N/ANot applicable: PM4 requires a protein-length change, and this is a missense variant. Details ▾Hide ▴
Reasoning

PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_001003841.3:c.517G>A in SLC6A19 is a missense substitution predicted to produce NP_001003841.1:p.(Asp173Asn). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for SLC6A19, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_stop_loss_or_nonrepeat_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP3 N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_001003841.3:c.517G>A in SLC6A19 is a missense substitution predicted to produce NP_001003841.1:p.(Asp173Asn). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for SLC6A19, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_repeat_region_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_001003841.3:c.517G>A in SLC6A19 is a missense substitution predicted to produce NP_001003841.1:p.(Asp173Asn). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for SLC6A19, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Identifiers

Gene
SLC6A19
Transcript
NM_001003841.3
Coding (HGVS c.)
NM_001003841.3:c.517G>A
Protein (HGVS p.)
NP_001003841.1:p.(Asp173Asn)
GRCh38
chr5:1212338 G>A
GRCh37
chr5:1212453 G>A
Location and type
Exon 4 · missense
ClinVar
2019

Gene diagram

Every interpreted variant in SLC6A19, mapped onto the exon structure of NM_001003841.3. Select a row to find it on the plot.

SLC6A19NM_001003841.3
Fetching transcript structure from UCSC…
gnomAD v4.1 5,008 / 1,613,638 alleles AF 0.0031 · 12 homozygotes · FAF 0.00396
gnomAD v2.1 441 / 282,308 alleles AF 0.00156 · 0 homozygotes · FAF 0.00281
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 0.0031 · 5008 / 1,613,638 alleles · 12 hom · FAF 0.004
European (non-Finnish)4784 / 1,179,944 0.004112 hom
Remaining individuals105 / 62,496 0.0017
Ashkenazi Jewish21 / 29,602 0.00071
African/African American44 / 75,016 0.00059
Admixed American19 / 60,016 0.00032
South Asian26 / 91,086 0.00029
Middle Eastern1 / 6,062 0.00016
European (Finnish)8 / 63,622 0.00013
0 alternate alleles recorded in 2 other groups: Amish, East Asian.

gnomAD v2.1

AF 0.0016 · 441 / 282,308 alleles · 0 hom · FAF 0.0028
European (non-Finnish)389 / 128,998 0.003
Remaining individuals7 / 7,220 0.00097
Ashkenazi Jewish8 / 10,356 0.00077
African/African American18 / 24,922 0.00072
Admixed American11 / 35,418 0.00031
South Asian5 / 30,616 0.00016
European (Finnish)3 / 24,828 0.00012
0 alternate alleles recorded in 1 other group: East Asian.

gnomAD-Canada

AF not recorded · ? / ? alleles

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 0.00310355; MAF= 0.31035%, 5008/1613638 alleles, homozygotes = 12) and has highest observed frequency in the European (non-Finnish) population (AF= 0.00405443; MAF= 0.40544%, 4784/1179944 alleles, homozygotes = 12); grpmax FAF= 0.00395819.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.00156212; MAF= 0.15621%, 441/282308 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 0.00301555; MAF= 0.30156%, 389/128998 alleles, homozygotes = 0); grpmax FAF= 0.00280627.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.0018464212012599109, 34/18414 alleles, homozygotes = 0).

Open the gnomAD-Canada detail page →

SpliceAI and Pangolin

SpliceAI acceptor lossat -35 bp
0.004
SpliceAI acceptor gainat +47 bp
0.005
SpliceAI donor lossat +10 bp
0.000
SpliceAI donor gainat +174 bp
0.004
Pangolin splice lossmagnitude shown
-0.017
Pangolin splice gain
0.001

Other predictors

REVEL
0.179
BayesDel
-0.286

How the predictions were used

BP4 ModerateACMGMet at moderate strength: REVEL 0.179 meets the generic BP4 moderate threshold of <=0.183 for missense variants. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NM_001003841.3:c.517G>A (NP_001003841.1:p.(Asp173Asn)), so the generic missense path requires REVEL and does not use SpliceAI. REVEL is 0.179, which meets the supplied generic BP4 moderate threshold of <= 0.183; therefore BP4 is met at moderate strength. The SpliceAI result is not counted on this path, and BayesDel is not used because no generic ACMG-strength calibration is established.

Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc) ... BP4 (moderate): <= 0.183 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Consequence classification: missense variant NM_001003841.3:c.517G>A, producing NP_001003841.1:p.(Asp173Asn).
  • Local REVEL lookup reports score 0.179 for chr5:1212338 G>A.
  • The supplied generic calibration gives BP4 moderate at REVEL <= 0.183; ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet; PMID:36413997).
  • SpliceAI max delta 0.005 was not used because the governing generic path for a missense variant is REVEL only; BayesDel was not used because no generic ACMG-strength calibration is established.
Sources
revel
PP3 ACMGNot met: REVEL 0.179 is below the generic PP3 supporting threshold of >=0.644 for missense variants. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NM_001003841.3:c.517G>A (NP_001003841.1:p.(Asp173Asn)), so the generic missense path requires REVEL and does not use SpliceAI. REVEL is 0.179, below the generic PP3 supporting threshold of >= 0.644; therefore PP3 is not met. BayesDel is not used because no generic ACMG-strength calibration is established, and the SpliceAI result is not counted on the missense path.

Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.). ... PP3 (supporting): >= 0.644 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Consequence classification: missense variant NM_001003841.3:c.517G>A, producing NP_001003841.1:p.(Asp173Asn).
  • Local REVEL lookup reports score 0.179 for chr5:1212338 G>A.
  • The supplied generic calibration gives PP3 supporting at REVEL >= 0.644; ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet; PMID:36413997).
  • SpliceAI max delta 0.005 was not used because the governing generic path for a missense variant is REVEL only; BayesDel was not used because no generic ACMG-strength calibration is established.
Sources
revel
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_001003841.3:c.517G>A in SLC6A19 is a missense substitution predicted to produce NP_001003841.1:p.(Asp173Asn). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for SLC6A19, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01). REVEL score = 0.179. BayesDel score = -0.285677.

8 paper records listed. 1 cited in the classification.

Cited in the classification

  • Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with hartnup mutations.
    Camargo SM et al. · 2009 Mar
    The paper identifies SLC6A19 c.517G>A as the B0AT1 D173N missense mutation and evaluates its transport and cell-surface expression in Xenopus laevis oocytes. D173N has relatively low transport activity alone; coexpression with ACE2 increases transport and surface expression, whereas collectrin does not.
    → PS3 · supporting Names this variant
    PMID 19185582 ↗
    Source detail
    The relatively low transport activity of B0AT1 D173N and P265L mutants expressed alone is increased by coexpression with ACE2 but not with collectrin. The surface expression of the D173N mutant is also significantly increased by coexpression with ACE2.

    Location Table 1; Results, “Differential Interaction of Accessory Proteins With B0AT1 Hartnup Mutations”; Figure 2B and 2D; Figure 3

    Context Functional studies in Xenopus laevis oocytes expressing human wild-type or mutant B0AT1 alone or with human collectrin or mouse/human ACE2; radiolabeled L-isoleucine uptake, two-microelectrode voltage clamp, surface-protein biotinylation, and coimmunoprecipitation.

Other recorded publications

  • Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19.
    Seow HF et al. · 2004
    No paper-specific finding is recorded.
    PMID 15286788 ↗
  • Persistence of the common Hartnup disease D173N allele in populations of European origin.
    Azmanov DN et al. · 2007
    The paper reports the SLC6A19 D173N missense allele in 42% of Hartnup chromosomes from apparently unrelated families in Australia and North America, documenting a recurrent disease-associated missense allele.
    Names this variant
    PMID 17555458 ↗
    Quoted passage
    One mutation, the D173N allele, is present in 42% of Hartnup chromosomes from apparently unrelated families from both Australia and North America.

    Abstract

  • Further evidence for allelic heterogeneity in Hartnup disorder.
    Azmanov DN et al. · 2008
    The abstract states that SLC6A19 mutations have been shown to cosegregate with Hartnup disease in the predicted recessive manner, but also reports that not all causative alleles were identified in all affected individuals in two previous studies. The available evidence does not identify variant-specific affected and unaffected relatives or provide informative meioses for c.517G>A (p.Asp173Asn).
    Does not name this variant
    PMID 18484095 ↗
    Quoted passage
    Mutations in SLC6A19 have been shown to cosegregate with the disease in the predicted recessive manner; however, in two previous studies (Seow et al., Nat Genet 2004;36:1003-1007; Kleta et al., Nat Genet 2004;36:999-1002), not all causative alleles were identified in all affected individuals

    Abstract

  • Collectrin and ACE2 in renal and intestinal amino acid transport.
    Singer D et al. · 2011
    No paper-specific finding is recorded.
    PMID 21814048 ↗
  • A systematic approach to assessing the clinical significance of genetic variants.
    No paper-specific finding is recorded.
    PMID 24033266 ↗
  • Rare mutations associating with serum creatinine and chronic kidney disease.
    Sveinbjornsson G et al. · 2014
    No paper-specific finding is recorded.
    PMID 25082825 ↗
  • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
    No paper-specific finding is recorded.
    PMID 25741868 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 0.00310355; MAF= 0.31035%, 5008/1613638 alleles, homozygotes = 12) and has highest observed frequency in the European (non-Finnish) population (AF= 0.00405443; MAF= 0.40544%, 4784/1179944 alleles, homozygotes = 12); grpmax FAF= 0.00395819.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0.00156212; MAF= 0.15621%, 441/282308 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 0.00301555; MAF= 0.30156%, 389/128998 alleles, homozygotes = 0); grpmax FAF= 0.00280627.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 0.0018464212012599109, 34/18414 alleles, homozygotes = 0).

ClinVar

This variant has been reported in ClinVar as Pathogenic (18 clinical laboratories) and as Likely pathogenic (1 clinical laboratory) and as Uncertain significance (1 clinical laboratory). (ClinVarID = 2019)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01). REVEL score = 0.179. BayesDel score = -0.285677.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.